Literature DB >> 387223

Toxic effects of cis-dichlorodiammineplatinum(II) in man.

D D Von Hoff, R Schilsky, C M Reichert, R L Reddick, M Rozencweig, R C Young, F M Muggia.   

Abstract

Administration of cis-dichlorodiammineplatinum(II) may be associated with a number of serious side effects, including nephrotoxicity, gastroeintestinal side effects (nausea, vomiting, and diarrhea), myelosuppression, and occasional transient elevations in liver function tests. In addition, ototoxicity (tinnitus and hearing loss), anaphylactic reactions, peripheral neuropathies, and hypomagnesemia with resulting tetany may also be encountered. The toxic potential of this new agent necessitates careful clinical monitoring during treatment.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 387223

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  107 in total

1.  Protection against cisplatin-induced lipid peroxidation and kidney damage by procaine in rats.

Authors:  L F Zhong; J G Zhang; M Zhang; S L Ma; Y X Xia
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

2.  DNA molecular recognition and cellular selectivity of anticancer metal(II) complexes of ethylenediaminediacetate and phenanthroline: multiple targets.

Authors:  Sze-Tin Von; Hoi-Ling Seng; Hong-Boon Lee; Seik-Weng Ng; Yusuke Kitamura; Makoto Chikira; Chew-Hee Ng
Journal:  J Biol Inorg Chem       Date:  2011-08-11       Impact factor: 3.358

3.  Determination of cis-diamminedichloroplatinum (II) in plasma proteins and hemoglobin of cancer patients.

Authors:  R Mustonen; P Hietanen; S Leppälä; M Takala; K Hemminki
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

4.  Progressive paresthesias after cessation of therapy with very high-dose cisplatin.

Authors:  S M Grunberg; S Sonka; L L Stevenson; F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  Cancer, chemotherapy and anaesthesia.

Authors:  F Chung
Journal:  Can Anaesth Soc J       Date:  1982-07

6.  Balloon-occluded arterial infusion therapy in the treatment of primary and recurrent gynecologic malignancies.

Authors:  Y Yamashita; M Takahashi; H Bussaka; Y Korogi; R Saito; K Miyazaki; S Fujisaki; H Okamura
Journal:  Cardiovasc Intervent Radiol       Date:  1989 Jul-Aug       Impact factor: 2.740

7.  Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide.

Authors:  H T Heidemann; J F Gerkens; E K Jackson; R A Branch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

8.  Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.

Authors:  Joan Carles; Cristina Suárez; Carlos Mesía; Miquel Nogué; Albert Font; Montserrat Doménech; Marta Suárez; Ignasi Tusquets; M Gallén; Joan Albanell; Xavier Fabregat
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

9.  Increased therapeutic effect on metastatic liver tumors in rats of two-route chemotherapy using cis-diamminedichloroplatinum (II) and its antidote, sodium thiosulfate, with temporary clamping of the abdominal aorta.

Authors:  K Hasuda; H Kobayashi; K Aoki; S Taniguchi; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.

Authors:  C L Bregman; P D Williams
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.